Jonathan Yeh

Jonathan Yeh is a Managing Partner at Saisei Ventures, a venture capital firm focused on early-stage companies aiming to enhance health outcomes. Additionally, Jonathan is the Co-Founder & Board Observer at Kenai Therapeutics, which specializes in iPSC-based cell replacement therapy for neurological diseases like Parkinson's Disease. Previously, Jonathan held positions at 株式会社ヘリオス, CCRM, IRICoR, and the Leucegene Project, showcasing their expertise in investments, business development, and project leadership. With a strong academic background, including a PhD in Experimental Medicine from McGill University, Jonathan is well-equipped for their role in the healthcare and biotechnology sectors.